Liver toxicity of initial antiretroviral drug regimens including two nucleoside analogs plus one non-nucleoside analog or one ritonavir-boosted protease inhibitor in HIV/HCV-coinfected patients

HIV Clinical Trials

Volumn 13, Issue 2, 2012, Pages 61-69

  Macías, Juan ^a   Neukam, Karin ^a   Mallolas, Josep ^b   López Cortés, Luis F ^c   Cartón, José A ^d   Domingo, Pere ^e   Moreno, Santiago ^f   Iribarren, José A ^g   Clotet, Bonaventura ^h   Crespo, Manell ⁱ   De Los Santos, Ignacio ^j   Ortega, Enrique ^k   Knobel, Hernando ^l   Jiménez Expósito, María J ^m   Pineda, Juan A ^a  

^a HOSPITAL UNIVERSITARIO DE VALME   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

^c HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^d HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^e HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^f HOSPITAL RAMÓN Y CAJAL   (Spain)

^g HOSPITAL DONOSTIA   (Spain)

^h HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

ⁱ HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^j HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^k HOSPITAL GENERAL UNIVERSITARIO DE VALENCIA   (Spain)

^l HOSPITAL DEL MAR   (Spain)

^m Bristol Meyers Squibb   (Spain)

more..

Author keywords

efavirenz; hepatitis C virus; liver toxicity; nevirapine; ritonavir boosted protease inhibitors

Indexed keywords

ABACAVIR PLUS LAMIVUDINE; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; NEVIRAPINE; NUCLEOSIDE ANALOG; PROTEINASE INHIBITOR; RITONAVIR; STAVUDINE; TENOFOVIR; VIRUS RNA;

ANTIVIRAL THERAPY; ARTICLE; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; COMBINATION CHEMOTHERAPY; DECOMPENSATED LIVER CIRRHOSIS; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; LIVER FAILURE; LIVER FIBROSIS; LIVER TOXICITY; MAJOR CLINICAL STUDY; MIXED INFECTION; OBSERVATIONAL STUDY; PRESCRIPTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SIDE EFFECT;

ADULT; ANTI-HIV AGENTS; COINFECTION; DRUG THERAPY, COMBINATION; DRUG-INDUCED LIVER INJURY; FEMALE; HEPATITIS C; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; ODDS RATIO; RETROSPECTIVE STUDIES; RISK FACTORS; RITONAVIR;

EID: 84859863456     PISSN: 15284336     EISSN: 19455771     Source Type: Journal    
DOI: 10.1310/hct1302-61     Document Type: Article

References (20)

1. Thein HH, Yi Q, Dore GJ, Krahn MD. Natural history of hepatitis C virus infection in HIV-infected individuals and the impact of HIV in the era of highly active antiretroviral therapy: A meta-analysis. AIDS. 2008;22:1979-1991.
2. Macías J, Berenguer J, Japón MA, et al. Fast fibrosis progression between repeated liver biopsies in patients coinfected with human immunodeficiency virus/hepatitis C virus. Hepatology. 2009;50:1056-1063.
3. Pineda JA, García-García JA, Aguilar-Guisado M, et al. Clinical progression of hepatitis C virus-related chronic liver disease in human immunodeficiency virus-infected patients undergoing highly active antiretroviral therapy. Hepatology. 2007;46:622-630.
4. Dieleman JP, Jambroes M, Gyssens IC, et al. Determinants of recurrent toxicity-driven switches of highly active antiretroviral therapy. The ATHENA cohort. AIDS. 2002;16:737-745.
5. Jain MK. Drug-induced liver injury associated with HIV medications. Clin Liver Dis. 2007;11:615-639.
6. Soriano V, Koeppe S, Mingrone H, et al. Prospective comparison of nevirapine and atazanavir/ritonavir both combined with tenofovir DF/emtricitabine in treatmentnaïve HIV-1 infected patients: ARTEN study week 48 results. Presented at: 5th International AIDS Society Conference on HIV Pathogenesis, Treatment, and Prevention (IAS) 2009; July 19-22, 2009; Cape Town, South Africa. Abstract LBPEB07.
7. van Leth F, Phanuphak P, Ruxrungthan K, et al. Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: A randomized open-label trial, the 2NN study. Lancet. 2004;363:1253-1263.
8. da Silva B, King M, Cernohous P, et al. Lopinavir/ritonavir (LPV/r) safety, tolerability and efficacy in HIV patients co-infected with hepatitis C and/or hepatitis B: Review of clinical trials. In: Program and abstracts of the The XV International AIDS Conference; 2004; Bangkok. Abstract MoPeB3285.
9. Norris D, Patel L, Rizzardini G, et al. Efficacy and safety of fosamprenavir/ritonavir (FPV/r) bid or lopinavir/ritonavir (LPV/r) bid in antiretroviral treatment-naïve subjects co-infected with hepatitis B (HBV) or C (HCV) and HIV (the KLEAN study). In: Program and abstracts of the 4th International AIDS Society (IAS) Conference on HIV Pathogenenesis, Treatment and Prevention; 2007; Sydney. Abstract MOPEB059.
10. Absalon J, Thal G, Thiry A, et al. Atazanavir is safe and efficacious in HBV and HCV co-infected patients: Results of A1424138 (CASTLE). In: Program and abstracts of the 9th International Congress on Drug Therapy in HIV Infection; 2008; Glasgow. Abstract P136.
11. Ortiz R, Fourie J, Andrade-Villanueva J, et al. Tolerability of once-daily darunavir/r versus lopinavir/r in treatment naïve patients coinfected with hepatitis B and/or C in the ARTEMIS trial. In: Program and abstracts of the HEP DART: Frontiers in Drug Development for Viral Hepatitis; 2007; Hawaii. Abstract 97.
12. Pineda JA, Santos J, Rivero A, et al. Liver toxicity of antiretroviral combinations including atazanavir/ritonavir in patients co-infected with HIV and hepatitis viruses: Impact of pre-existing liver fibrosis. J Antimicrob Chemother. 2008;61:925-932.
13. Palacios R, Vergara S, Rivero A, et al. Low incidence of severe liver events in HIV patients with and without hepatitis C or B coinfection receiving lopinavir/ritonavir. HIV Clin Trials. 2006;7:319-323.
14. Sulkowski MS, Thomas DL, Mehta SH, Chaisson RE, Moore RD. Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: Role of hepatitis C and B infections. Hepatology. 2002;35:182-189.
15. Martín-Carbonero L, Nuñez M, González-Lahoz, et al. Incidence of liver injury after beginning antiretroviral therapy with efavirenz or nevirapine. HIV Clin Trials. 2003;4:115-278.
16. Martinez E, Blanco J, Arnaiz J, et al. Hepatotoxicity in HIV-infected patients receiving nevirapine containing antiretroviral therapy. AIDS. 2001;15:1261-1268.
17. Scheuer PJ. Classification of chronic viral hepatitis: A need for reassessment. J Hepatol. 1991;13:372-374.
18. Sustiva [efavirenz] capsules and tablet. Safety labeling changes approved by FDA Center for Drug Evaluation and Research (CDER). March 2010. http:// www.fda.gov/ Safety/ MedWatch/ SafetyInformation/ ucm208409.htm. Accessed at May 18, 2010.
19. FDA Public Health Advisory for nevirapine [Viramune]. http:// www.fda.gov/ Drugs/ DrugSafety/ PublicHealthAdvisories/ ucm051674.htm. Accessed at May 18, 2010.
20. Chalasani N, Björnsson E. Risk factors for idiosyncratic drug-induced liver injury. Gastroenterology. 2010;138:2246-2259.